含氯法齐明的短程方案治疗耐多药结核的随机对照试验
在中国开展的前瞻性随机多中心研究,纳入135例耐多药结核患者,比较含氯法齐明12个月方案与标准18个月方案。
要点
- 含氯法齐明12个月短程方案治疗成功率和标准18个月方案相当。
- 短程方案3个月痰培养转阴率显著更高,提示早期杀菌活性更强。
- 两组不良事件总发生率无显著差异。
核心结论
- 含氯法齐明的短程方案治疗耐多药结核的疗程结束成功率和标准方案相当,且痰培养转阴更快。
研究设计与样本
- 前瞻性随机多中心研究,在中国纳入135例符合条件耐多药结核患者,随机分为对照组(18个月方案)和实验组(含氯法齐明12个月方案)。
主要发现
- 治疗结束时实验组与对照组痰培养转阴率差异无统计学意义。
- 研究共报告67例不良事件(56例患者),对照组32例、实验组35例,两组总不良事件发生率无显著差异。
临床怎么用
- 含氯法齐明12个月短程方案可作为耐多药结核治疗选择,尤其关注早期痰菌转阴。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The emergence of multidrug-resistant tuberculosis (MDR-TB) poses a serious obstacle to global TB control programs. METHODS: We carried out a prospective, randomized, multicenter study in China that was focused on the potential of a shorter regimen containing clofazimine (CFZ) for the treatment of MDR-TB. There were 135 MDR-TB cases that met eligibility requirements and were randomly stratified into either the control group or experimental group. Patients in the control group received an 18-month treatment regimen, whereas patients in the experimental group received a 12-month treatment regimen containing CFZ. RESULTS: At the completion of the treatment period, the difference in sputum-culture conversion rates between the experimental group and the control group was not significant. Notably, by the end of 3 months of treatment, 68.7% patients receiving the experimental regimen had sputum-culture conversion, as compared with 55.9% of those receiving the control regimen; this was a significant difference, suggesting an early sputum conversion (P = .04). There were 67 adverse events reported in 56 patients in this study, including 32 in the control group and 35 in the experimental group. No significant difference in the overall incidences of adverse events was observed between the 2 groups. CONCLUSIONS: The MDR-TB patients treated with the shorter regimen containing CFZ had a comparable successful outcome rate when compared to those with the standard regimen. The patients assigned to the experimental group achieved more rapid sputum-culture conversion, reflecting superior antimicrobial activity against MDR-TB. CLINICAL TRIALS REGISTRATION: Chinese Clinical Trial Registry ChiCTR 1800020391.
引用
- Du Y, Qiu C, Chen X, et al. Treatment Outcome of a Shorter Regimen Containing Clofazimine for Multidrug-resistant Tuberculosis: A Randomized Control Trial in China. Clin Infect Dis. 2020. PMID: 31549147. doi:10.1093/cid/ciz915
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。